Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration

Fadiman and colleagues frame microdosing as the administration of a subperceptual fraction of a typical recreational psychedelic dose, intended to produce no classic psychedelic visuals or intense perceptual changes. They define typical microdose ranges as about 7–13 micrograms for LSD and 0.1–0.4 grams for dried psilocybin mushrooms, and note that early laboratory research looked for perceptual and physiological effects similar to high doses and therefore concluded that doses lower than about 25 µg produced no discernible effects. The Introduction situates the present work within this historical context and highlights a gap: despite widespread informal use and anecdotal reports, systematic and large-scale observational data on microdosing were lacking until recently. This article reports on an open, exploratory programme that began with correspondence and informal reports and evolved into more structured, crowd-sourced data collection. The stated aim is to review what has been learned from initial open exploratory reports, the subsequent more structured self-study protocol, and the planned follow-up studies, focusing on findings for which the authors judged there were sufficient reports to generalise. Participants were still enrolling as the authors wrote, so the results are presented as preliminary and "in progress."

The study began as an open, worldwide, self-directed microdosing programme in which interested individuals were offered a suggested protocol and asked to keep records. The recommended regimen used for the structured self-study was: take a microdose on day 1, abstain on days 2 and 3, and repeat the cycle for one month. This schedule derived from early reports suggesting effects lasting up to two days and the intention that day 3 represent a return to baseline so participants could better observe changes when dosing again. After the initial month participants were left to decide their own ongoing dosing frequency; many who continued reported switching to once-weekly or monthly dosing. Enrolment materials requested demographic information, self-reported mental and physical conditions in the preceding month, reasons for microdosing, and daily ratings of positive and negative emotional states using the PANAS 2.0 checklist. Participants could also provide free-text journal entries; some tracked additional personal variables such as pain or blood glucose. The sample included adults aged 18–80 from multiple countries, and individuals used a variety of psychedelic substances and dosing practices, not all of which matched the suggested protocol. Data collected for analysis comprised hundreds of long-form journal entries and thousands of daily PANAS data points. The investigators emphasised triangulation of qualitative journal material with quantitative PANAS scores to enrich description, but the extracted text does not clearly report formal statistical models, pre-specified analytic methods beyond this triangulation, or whether an intention-to-treat framework was applied. The study was observational and unblinded: participants self-administered doses and self-reported outcomes rather than receiving measured doses under experimental control.

The dataset included hundreds of long-form self-report journals and thousands of PANAS check-ins from hundreds of participants. Participants came from a wide age range and diverse life circumstances. The extracted text states that 80% of submitted stories were categorised as positive or neutral, with the remainder described as negative; typical positive narratives described increases in positive mood, reductions in negative mood, improved social interactions, greater patience, reduced headaches, enhanced productivity and creativity, and a decision after the initial month to continue microdosing less frequently. Mood change was a prominent theme. Many participants reported elevation in mood and reductions in negative affect that persisted beyond 14 days. This included people who reported diagnoses of major depressive disorder, bipolar disorder, and other mood disorders as well as people without diagnoses. The authors cautioned against equating statistical significance with clinical significance but nevertheless noted multiple participants who described microdosing as an effective antidepressant or as facilitating tapering from prescribed antidepressants. Participants with bipolar disorder reported benefits for depressive periods but not for manic or hypomanic episodes; several adjusted dose or frequency out of concern about mood elevation, and none reported onset of mania or hypomania during the study period. Work-related effects were commonly reported: many participants seeking help with attention, ADHD or productivity described less procrastination, better task completion and increased creativity. Some reported substituting microdosing for prescribed stimulants and experiencing fewer ‘‘crashes.’’ Home-life effects reported included greater patience and improved interpersonal openness, corroborated anecdotally by family members in some cases. Reports on medical conditions were mixed. For most people with chronic pain there was no observable change in daily pain scores, though many reported improved mood accompanying chronic pain. A subset of participants reported clinically notable changes in neuropathic pain conditions, including lancinating pain from herpes zoster (shingles) and other neuropathic syndromes; individual narratives also described reductions in opioid use. Adverse or neutral experiences were present: some people experienced nervous energy, sleep disruption if dosing late in the day, unpleasant physical symptoms (noted more often with mushrooms), and increased anxiety in a minority of cases. The extracted text notes that many participants stopped reporting before the end of the month and that reporting frequency varied across the sample.

The authors interpret these results as an initial, real-world characterisation of a rapidly evolving microdosing phenomenon. They situate their findings within a shifting research landscape: crowdsourced, open-enrolment studies are giving way to university-sponsored trials that will administer measured doses of LSD, psilocybin or placebo under controlled conditions and assess physiological and psychological outcomes. In the interim the authors view real-world evidence as valuable, arguing that some patient-centred effects may not be fully captured by traditional pharmaceutical trial instruments. Limitations acknowledged include the observational, unblinded and self-selected nature of the data; reliance on self-report; variable adherence to the suggested protocol; and incomplete follow-up because many participants stopped reporting. The authors explicitly note that placebo effects cannot be excluded and that statistical significance does not necessarily imply clinically meaningful change. They further emphasise uncertainty about whether reported effects are substance-, dose- or schedule-dependent and that the mechanisms underlying reported improvements—particularly in treatment-resistant depression and certain pain syndromes—remain unknown. Looking forward, the investigators describe ongoing and planned work: advising controlled trials, implementing a large-scale multi-site follow-up survey spanning 59+ countries to examine longer-term outcomes across multiple diagnostic groups, improving participant communication and feedback mechanisms, and pre-registering hypotheses and uploading de-identified data and analyses to the Open Science Framework. They frame these steps as necessary to discover longer-term benefits and risks and to provide data that controlled trials can test more rigorously.